Skip to main content


  • Poster presentation
  • Open Access

Effectiveness of continuous venovenous hemodiafiltration using a polymethylmethacrylate membrane hemofilter in septic shock patients

  • 1,
  • 1,
  • 2,
  • 1 and
  • 3
Critical Care200812 (Suppl 2) :P457

  • Published:


  • PMMA
  • Polyacrylonitrile
  • Septic Shock Patient
  • Sofa Score
  • Blood Purification


Septic shock is a condition associated with diffuse coagulopathy and multiple organ failure, and frequently ends in death. The effectiveness of continuous venovenous hemodiafiltration (CVVHDF) using a polymethylmethacrylate membrane hemofilter (PMMA) for critically ill patients has also been reported.


We treated 18 septic shock patients by CVVHDF. The patients were divided into two groups: namely, a group in which CVVHDF using PMMA therapy was added (11 cases), and a group in which CVVHDF using a polyacrylonitrile membrane hemofilter (CVVHDF using PAN) therapy was added (seven cases). The outcomes in the two groups were compared.


The average APACHE II score and the average SOFA score were not significantly different between the two groups. The CVVHDF using PMMA group showed significantly better outcomes, with significant improvements of the serum plasminogen activator inhibitor 1 (PAI-1), protein C, IL-6 and N-arachidonoylethanolamine (AEA) levels.


Therapies aimed at blood purification, such as CVVHDF, continuous hemofiltration and plasma exchange have been reported to be effective for the removal of inflammatory cytokines and various mediators. Few reports have shown the influence of the column used for CVVHDF on the removal efficiency of the abovementioned factors, although several columns have been used in CVVHDF. CVVHDF using PMMA has been reported to be effective for cytokine removal. Our findings suggest removal of IL-6, AEA and PAI-1 by CVVHDF using PMMA; and CVVHDF using PMMA resulted in better outcomes and an improved survival rate in septic shock patients.

Authors’ Affiliations

Nippon Medical School, Chiba Hokusou Hospital, Chiba, Japan
Jikei University School of Medicine, Institute of DNA Medicine, Tokyo, Japan
Nippon Medical School, Tokyo, Japan


  1. Matsuda K, et al.: Current topics on cytokine removal technologies. Ther Apher 2001, 5: 306-314. 10.1046/j.1526-0968.2001.00361.xPubMedView ArticleGoogle Scholar


© BioMed Central Ltd 2008

This article is published under license to BioMed Central Ltd.